Articles related to BREAST CANCER

Women with hormone-sensitive breast cancers face complex decisions weighing cardiovascular mortality risk against potential cancer recurrence when considering systemic hormone therapy.

Healthcare providers demonstrate different treatment approaches based on patient demographics and perceived medical knowledge, requiring systematic advocacy training.

Previous research on omega-6 fatty acids has produced mixed results and often lacked clarity on how these fats affect cancer risk… this research is focused on clearing up those uncertainties.

A comprehensive analysis of 176,601 cancer cases demonstrates that long-acting reversible contraceptives offer a cancer risk profile comparable to oral contraceptives, with data showing a 20-30% reduction in gynecologic cancer risk and a modest increase in breast cancer risk that returns to baseline after cessation.

The combination of imlunestrant plus abemaciclib demonstrated significant progression-free survival benefit across all subgroups, including patients with prior CDK4/6 inhibitor use and those with visceral metastases.

In a cohort of 601 women aged ≥65 years with low-risk breast cancer treated without radiotherapy, the 10-year local recurrence rate was 5.5%, with only 0.5% breast cancer-specific mortality.